Carna Bioscience To Out-License Kinase Inhibitor With ¥100 Million In Mind
This article was originally published in PharmAsia News
Executive Summary
Tokyo based Carna Biosciences Inc. is readying its kinase inhibitor for an out-licensing deal in 2012, disclosed company President Koichiro Yoshino during a Feb. 13 earnings call.